Trials / Completed
CompletedNCT03081819
A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Kyunghee University Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I study of SH003 for evaluate safe dose range in patients with solid cancer. The first dose group receives SH003 for 3 weeks. If the adverse events occur in less than one in six participants, the dose is escalated. The second dose group receives SH003 for 3 weeks. If the adverse events occur in less than one in six participants, the dose is escalated. The third dose group receives SH003 for 3 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SH003 | Herbal medicine for cancer treatment |
Timeline
- Start date
- 2017-03-29
- Primary completion
- 2019-04-16
- Completion
- 2019-07-25
- First posted
- 2017-03-16
- Last updated
- 2019-09-11
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03081819. Inclusion in this directory is not an endorsement.